APA (7th ed.) Citation

Mathieu, M. C., Goubar, A., Sigal, B., Bertheau, P., Guinebretière, J. M., André, F., . . . Marty, M. (2012). Role of pMAPkinase, pAKT, p27 & IGF-IR as predictive markers of response to trastuzumab in patients with HER2-positive invasive breast cancer treated with neoadjuvant chemotherapy + trastuzumab in the REMAGUS02 trial. Cancer Research, 72(24a), 877. https://doi.org/10.1158/0008-5472.SABCS12-P3-06-04

Chicago Style (17th ed.) Citation

Mathieu, M. C., et al. "Role of PMAPkinase, PAKT, P27 & IGF-IR as Predictive Markers of Response to Trastuzumab in Patients with HER2-positive Invasive Breast Cancer Treated with Neoadjuvant Chemotherapy + Trastuzumab in the REMAGUS02 Trial." Cancer Research 72, no. 24a (2012): 877. https://doi.org/10.1158/0008-5472.SABCS12-P3-06-04.

MLA (9th ed.) Citation

Mathieu, M. C., et al. "Role of PMAPkinase, PAKT, P27 & IGF-IR as Predictive Markers of Response to Trastuzumab in Patients with HER2-positive Invasive Breast Cancer Treated with Neoadjuvant Chemotherapy + Trastuzumab in the REMAGUS02 Trial." Cancer Research, vol. 72, no. 24a, 2012, p. 877, https://doi.org/10.1158/0008-5472.SABCS12-P3-06-04.